Pharma deal value rises 55.2% in July 2026: GlobalData

2026 Biopharma M&A Trends: Big Pharma’s $130 Billion H1 Deal Spree Nearly Tops All of 2025

Biopharma M&A activity has exploded in 2026, generating an estimated $130 billion across 42 major transactions. According to IQVIA’s mid-year transaction tracking, H1 deal value nearly matched the $133 billion recorded throughout 2025—in half the time. Average deal size climbed from $2.7 billion in 2025 to $3.1 billion, signaling a clear strategic shift. Rather than spreading capital across speculative early-stage pipelines, acquirers increasing…

Pharma deal value rises 55.2% in July 2026: GlobalData

The healthcare industry reported 87 deals worth $29.5 billion in July 2026, compared with the last 12 months’ average of 85 deals worth $29.6 billion, according to GlobalData. Deal value increased by 55.2 per cent in July 2026 compared with July 2025. Vertex Pharmaceuticals Inc agreed to acquire Crinetics Pharmaceuticals Inc, a pharmaceutical company focused on developing therapies for endocrine diseases, for $85 per share in cash, representing …